SAFETY DATA SHEETS

This SDS packet was issued with item:

078421195

The safety data sheets (SDS) in this packet apply to the individual products listed below. Please refer to invoice for specific item number(s).

078845477



SAFETY DATA SHEET

1. Identification

Product identifier Buscopan™ Injectable Solution

Other means of identification

Recommended use For the control abdominal pain associated with spasmodic colic, flatulent colic, and simple

impactions in horses.

Recommended restrictions None known.

Manufacturer/Importer/Supplier/Distributor information

Manufacturer Boehringer Ingelheim Vetmedica, Inc.

Address 2621 North Belt Hwy

St. Joseph, MO 64506-2002

Transportation emergency For Chemical Emergency Spill, Leak, Fire, Exposure, or Accident Call

CHEMTREC Day or Night

Within USA and Canada: 1-800-424-9300

Outside USA and Canada: +1 703-527-3887 (collect calls accepted)

Medical Emergency

(24HR):

(866)638-2226

Non-Emergency calls: (800) 821-7467

2. Hazard(s) identification

Physical hazards Not classified.

Health hazards Not classified.

OSHA defined hazards Not classified.

Label elements

Hazard symbol None.
Signal word None.

Hazard statement The mixture does not meet the criteria for classification.

Precautionary statement

Prevention Observe good industrial hygiene practices.

Response Wash hands after handling.

Storage Store away from incompatible materials.

Disposal Dispose of waste and residues in accordance with local authority requirements.

Hazard(s) not otherwise

classified (HNOC)

None known.

3. Composition/information on ingredients

Version #: 02 Revision date: 13-September-2016

Mixtures

925504

Chemical name	CAS number	%
N-Butylhyoscinium bromide	149-64-4	2

4. First-aid measures

Inhalation If breathing is difficult, remove to fresh air and keep at rest in a position comfortable for breathing.

Call a physician if symptoms develop or persist.

Skin contact Rinse skin with water/shower. Get medical attention if irritation develops and persists.

Eye contact Rinse with water. Get medical attention if irritation develops and persists.

Ingestion Rinse mouth. If ingestion of a large amount does occur, call a poison control center immediately.

Buscopan™ Injectable Solution SDS US

Most important symptoms/effects, acute and delayed

Direct contact with eyes may cause temporary irritation. Ingestion of a large quantity may cause vomiting, nausea, dizziness, drowsiness and other systemic effects.

Indication of immediate medical attention and special treatment needed

Not for human use. For use in animals only. Treat symptomatically. Persons developing anaphylactic (life threatening) reactions, such a as difficulty in breathing or unconsciousness, must receive immediate medical attention.

General information

Ensure that medical personnel are aware of the material(s) involved, and take precautions to protect themselves.

5. Fire-fighting measures

Suitable extinguishing media Unsuitable extinguishing

Water fog. Foam. Dry chemical powder. Carbon dioxide (CO2).

None known.

media

Specific hazards arising from the chemical

During fire, gases hazardous to health may be formed. Combustion products may include: carbon oxides, nitrogen oxides, and hydrogen bromide.

Special protective equipment and precautions for firefighters

Self-contained breathing apparatus and full protective clothing must be worn in case of fire.

Fire fighting

Move containers from fire area if you can do so without risk. equipment/instructions

Specific methods Use standard firefighting procedures and consider the hazards of other involved materials.

General fire hazards No unusual fire or explosion hazards noted.

6. Accidental release measures

Personal precautions, protective equipment and emergency procedures

Keep unnecessary personnel away. For personal protection, see section 8 of the SDS.

Methods and materials for containment and cleaning up

Large Spills: Stop the flow of material, if this is without risk. Dike the spilled material, where this is possible. Cover with plastic sheet to prevent spreading. Absorb in vermiculite, dry sand or earth and place into containers. Following product recovery, flush area with water.

Small Spills: Wipe up with absorbent material (e.g. cloth, fleece). Clean surface thoroughly to remove residual contamination.

Never return spills to original containers for re-use. For waste disposal, see section 13 of the SDS.

Environmental precautions

Avoid discharge into drains, water courses or onto the ground.

7. Handling and storage

Precautions for safe handling

Avoid prolonged exposure. Use care in handling/storage.

Conditions for safe storage, including any incompatibilities Store in original tightly closed container. Store away from incompatible materials (see Section 10

of the SDS). Keep from freezing.

8. Exposure controls/personal protection

Occupational exposure limits

No exposure limits noted for ingredient(s).

Biological limit values Appropriate engineering

controls

No biological exposure limits noted for the ingredient(s).

Good general ventilation (typically 10 air changes per hour) should be used. Ventilation rates should be matched to conditions. If applicable, use process enclosures, local exhaust ventilation, or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels to an acceptable level.

Individual protection measures, such as personal protective equipment

Eye/face protection

Wear safety glasses with side shields (or goggles).

Skin protection

Hand protection Wear appropriate chemical resistant gloves.

Other Wear suitable protective clothing.

Respiratory protection

If engineering controls do not maintain airborne concentrations below recommended exposure limits (where applicable) or to an acceptable level (in countries where exposure limits have not

been established), an approved respirator must be worn.

Thermal hazards

Wear appropriate thermal protective clothing, when necessary.

General hygiene considerations

Always observe good personal hygiene measures, such as washing after handling the material and before eating, drinking, and/or smoking. Routinely wash work clothing and protective

equipment to remove contaminants.

Buscopan™ Injectable Solution SDS US 2/6 925504 Version #: 02 Revision date: 13-September-2016 Issue date: 06-May-2015

9. Physical and chemical properties

Appearance

Physical state Liquid.

Form Liquid solution packaged in 50 mL bottle.

Color Colorless. Odorless. Odor Not available. **Odor threshold**

3.7 - 6рH

Not available. Melting point/freezing point Initial boiling point and boiling Not available.

range

Not available. Flash point **Evaporation rate** Not available. Flammability (solid, gas) Not applicable. Upper/lower flammability or explosive limits

Flammability limit - lower

Not available.

(%)

Flammability limit - upper

Not available.

(%)

Explosive limit - lower (%) Not available. Not available. Explosive limit - upper (%) Vapor pressure Not available. Not available. Vapor density 1.005 - 1.015 Relative density

Solubility(ies)

Not available. Solubility (water) Partition coefficient Not available.

(n-octanol/water)

Not available. **Auto-ignition temperature Decomposition temperature** Not available. Not available. **Viscosity**

10. Stability and reactivity

Reactivity Chemical The product is stable and non-reactive under normal conditions of use, storage and transport.

stability Possibility of

Material is stable under normal conditions.

hazardous

No dangerous reaction known under conditions of normal use.

reactions

Conditions to avoid Contact with incompatible materials.

Incompatible materials Strong oxidizing agents.

Hazardous decomposition

products

925504

No hazardous decomposition products are known.

11. Toxicological information

Information on likely routes of exposure

Inhalation No adverse effects due to inhalation are expected. Skin contact No adverse effects due to skin contact are expected. Eve contact Direct contact with eyes may cause temporary irritation.

Ingestion Expected to be a low ingestion hazard.

Symptoms related to the physical, chemical and toxicological characteristics Direct contact with eyes may cause temporary irritation. Ingestion of a large quantity may cause

vomiting, nausea, dizziness, drowsiness and other systemic effects.

Information on toxicological effects

Buscopan™ Injectable Solution SDS US Version #: 02 Revision date: 13-September-2016

Acute toxicity Not expected to be acutely toxic.

Components Species **Test Results**

N-Butylhyoscinium bromide (CAS 149-64-4)

Acute

Oral

LD50 Rat 1040 mg/kg

Skin corrosion/irritation

Prolonged skin contact may cause temporary irritation.

Serious eye damage/eye

irritation

Direct contact with eyes may cause temporary irritation.

Respiratory or skin sensitization

Respiratory sensitization Not a respiratory sensitizer.

Skin sensitization This product is not expected to cause skin sensitization.

Germ cell mutagenicity No data available to indicate product or any components present at greater than 0.1% are

mutagenic or genotoxic.

Carcinogenicity This product is not considered to be a carcinogen by IARC, ACGIH, NTP, or OSHA.

OSHA Specifically Regulated Substances (29 CFR 1910.1001-1050)

Not listed.

This product is not expected to cause reproductive or developmental effects. Reproductive toxicity

Specific target organ toxicity -

single exposure

Not classified.

Specific target organ toxicity -

repeated exposure

Not classified.

Aspiration hazard Not an aspiration hazard.

Chronic effects Possible hypersensitization (development of abnormal sensitivity).

12. Ecological information

Ecotoxicity The product is not classified as environmentally hazardous. However, this does not exclude the

possibility that large or frequent spills can have a harmful or damaging effect on the environment.

Persistence and degradability

No data is available on the degradability of this product. No data available.

Bioaccumulative potential

Other adverse effects

No data available.

Mobility in soil

No other adverse environmental effects (e.g. ozone depletion, photochemical ozone creation potential, endocrine disruption, global warming potential) are expected from this component.

13. Disposal considerations

Collect and reclaim or dispose in sealed containers at licensed waste disposal site. **Disposal instructions**

Local disposal regulations

Dispose in accordance with all applicable regulations.

Hazardous waste code

The waste code should be assigned in discussion between the user, the producer and the waste

disposal company.

Waste from residues / unused

products

Dispose of in accordance with local regulations. Empty containers or liners may retain some product residues. This material and its container must be disposed of in a safe manner (see:

Disposal instructions).

Contaminated packaging Empty containers should be taken to an approved waste handling site for recycling or disposal.

Since emptied containers may retain product residue, follow label warnings even after container is

emptied.

14. Transport information

DOT

Not regulated as dangerous goods.

IATA

Not regulated as dangerous goods.

IMDG

Not regulated as dangerous goods.

Buscopan™ Injectable Solution SDS US 4/6 925504 Version #: 02 Revision date: 13-September-2016

Transport in bulk according to Annex II of MARPOL 73/78 and

the IBC Code

Not established.

15. Regulatory information

US federal regulations One or more components are not listed on TSCA.

> Therefore, it can only be used for TSCA exempt purposes such as R&D or veterinary use. FEDERAL LAW RESTRICTS THIS DRUG TO USE BY OR ON ORDER OF LICENSED

VETERINARIANS.

TSCA Section 12(b) Export Notification (40 CFR 707, Subpt. D)

Not regulated.

OSHA Specifically Regulated Substances (29 CFR 1910.1001-1050)

CERCLA Hazardous Substance List (40 CFR 302.4)

Not listed.

Superfund Amendments and Reauthorization Act of 1986 (SARA)

Hazard categories Immediate Hazard - No

Delayed Hazard - No Fire Hazard - No Pressure Hazard - No Reactivity Hazard - No

SARA 302 Extremely hazardous substance

Not listed.

SARA 311/312 Hazardous Nο

chemical

SARA 313 (TRI reporting)

Not regulated.

Other federal regulations

Clean Air Act (CAA) Section 112 Hazardous Air Pollutants (HAPs) List

Not regulated.

Clean Air Act (CAA) Section 112(r) Accidental Release Prevention (40 CFR 68.130)

Not regulated.

Safe Drinking Water Act

Not regulated.

(SDWA)

US state regulations

US. Massachusetts RTK - Substance List

Not regulated.

US. New Jersey Worker and Community Right-to-Know Act

US. Pennsylvania Worker and Community Right-to-Know Law

Not listed.

US. Rhode Island RTK

Not regulated.

US. California Proposition 65

California Safe Drinking Water and Toxic Enforcement Act of 1986 (Proposition 65): This material is not known to contain any chemicals currently listed as carcinogens or reproductive toxins.

International Inventories

Country(s) or region	Inventory name	On inventory (yes/no)*
Australia	Australian Inventory of Chemical Substances (AICS)	Yes
Canada	Domestic Substances List (DSL)	Yes
Canada	Non-Domestic Substances List (NDSL)	No
China	Inventory of Existing Chemical Substances in China (IECSC)	No
Europe	European Inventory of Existing Commercial Chemical Substances (FINECS)	Yes

Buscopan™ Injectable Solution SDS US 925504 Version #: 02 Revision date: 13-September-2016 5/6

Obtained by Global Safety Management, www.globalsafetynet.com, (877) 683-7460

Country(s) or region Inventory name On inventory (yes/no)* Europe European List of Notified Chemical Substances (ELINCS) Inventory of Existing and New Chemical Substances (ENCS) Japan Yes Existing Chemicals List (ECL) Korea No New Zealand **New Zealand Inventory** Yes **Philippines** Philippine Inventory of Chemicals and Chemical Substances Yes (PICCS)

Toxic Substances Control Act (TSCA) Inventory

No

*A "Yes" indicates this product complies with the inventory requirements administered by the governing country(s).

A "No" indicates that one or more components of the product are not listed or exempt from listing on the inventory administered by the governing country(s).

16. Other information, including date of preparation or last revision

Issue date 06-May-2015

Revision date 13-September-2016

Version # 02

United States & Puerto Rico

Further information Refer to NFPA 654, Standard for the Prevention of Fire and Dust Explosions from the

Manufacturing, Processing, and Handling of Combustible Particulate Solids, for safe handling. HMIS® is a registered trade and service mark of the American Coatings Association (ACA).

HMIS® ratings Health: 1

Flammability: 1 Physical hazard: 0

NFPA ratings



Disclaimer

The information provided herein is offered by Boehringer Ingelheim Vetmedica, Inc. ("BIVI") in good faith as accurate as of the date hereof, but without guarantee. This information includes information which has been generated by other parties and provided to BIVI, and which BIVI has not independently verified. The information provided herein relates only to the specific product designated, and may not be valid where such product is used in combination with any other materials or in any process. The information provided herein is offered solely for your consideration, investigation and verification, and Boehringer Ingelheim Vetmedica, Inc. ("BIVI") expressly disclaims all liability for reliance thereon. BIVI EXPRESSLY DISCLAIMS ALL WARRANTIES OF EVERY KIND AND NATURE (INCLUDING WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE) WITH RESPECT TO THE USE OR SUITABILITY OF THE PRODUCT. In addition, since the conditions of use and suitability of the product for particular uses are beyond BIVI's control, ALL RISKS OF USE OF THE PRODUCT ARE THEREFORE ASSUMED BY THE USER, AND BIVI EXPRESSLY DISCLAIMS ANY AND ALL LIABILITY AS TO ANY RESULTS OBTAINED OR ARISING FROM ANY USE OF THE PRODUCT. Use or transmission of the information contained herein in any other format than the format as presented is strictly prohibited. Nothing herein shall be construed as permission or recommendation for the use of the product in a manner that might infringe an existing patent. BIVI neither represents nor warrants that the format, content or product formulas contained in this document comply with the laws of any other country except the United States of America.

Buscopan™ Injectable Solution SDS US

925504 Version #: 02 Revision date: 13-September-2016 Issue date: 06-May-2015 6 / 6